Arikayce’s Limited Population, Black Box Warning Won’t Limit Launch, Insmed Says
Because it will be initially targeting specialists and a very sick population, the biotech thinks Arikayce will get early usage in its narrowly defined lung infection indication.
You may also be interested in...
Several firms reporting quarterly earnings this week discussed how the outbreak is affecting supply chains, drug launches and clinical trials.
Public Company Edition: IPO performance has been mixed in 2019, but May has been the busiest month this year. Also, Insmed leads recent follow-on offerings and Dynavax restructures.
The latest drug development news and highlights from our FDA Performance Tracker.